[시장보고서]골다공증 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약품 클래스별, 유형별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

골다공증 치료제 시장 규모, 점유율, 동향 분석 보고서 : 약품 클래스별, 유형별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Osteoporosis Drugs Market Size, Share, & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

상품코드 : 1726177

리서치사 : Grand View Research

발행일 : 2025년 04월

페이지 정보 : 영문 100 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,572,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,013,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 12,895,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

골다공증 치료 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계 골다공증 치료 시장 규모는 2030년까지 188억 달러에 달할 것으로 예측되며, 2025-2030년의 CAGR은 3.5%를 나타낼 전망입니다.

건강에 해로운 라이프 스타일의 급증은 골다공증의 악화와 유병률 증가를 가져오고 예측 기간 동안 골다공증 치료 시장을 촉진하는 것으로 추정됩니다.

게다가, 특허 만료 증가에 의해 확립된 약제의 제네릭 의약품을 사용하는 임상상의 긴급성이 높아지고 있어 예측 기간중 제네릭 골다공증 치료 시장을 촉진하는 것으로 추측됩니다.

또한, 환자뿐만 아니라 의사들 사이에서 골다공증 치료에 대한 의식 수준을 높이는 노력이 증가하고 있다는 것도 예측 기간 동안 골다공증 시장의 성장 가능성을 넓힐 것으로 예측됩니다. 서비스(FLS)의 케어 조정 프로그램을 담당하는 의료 조직으로, 의식 레벨의 향상에 초점을 맞추고, 의료 전문가에게 트레이닝을 제공합니다.

골다공증 치료 시장 보고서 하이라이트

2024년 제품 부문에서는 브랜드 의약품이 압도적인 점유율을 차지합니다.
제네릭 의약품은 향후 수년간 일관되게 특허가 실효될 것, 또 신흥국에서 저렴한 의약품에 대한 임상상의 긴급성이 높기 때문에 유리한 CAGR을 나타낼 것으로 예측됩니다.
2024년에는 북미가 세계의 골다공증 치료 시장에서 최대의 점유율을 차지했지만, 이것은 브랜드 치료의 상업화에 널리 관여하고 있는 기존 기업의 존재에 의한 것입니다.
아시아태평양은 골다공증 치료와 관련된 정보를 촉진하는 유리한 정부 이니셔티브의 결과로 비약적인 CAGR로 성장할 것으로 예측됩니다.
주요 진출기업은 경쟁 우위를 얻기 위해 골다공증 치료의 채택을 촉진하는 지속가능성 전략을 채택하고 있습니다.

지역별 시장 점유율 분석, 2024년과 2030년
지역별 시장 대시보드
시장 규모와 예측 동향 분석, 2018-2030년
북미
- 국가별, 2018-2030년
- 미국
- 캐나다
- 멕시코
유럽
- 국가별, 2018-2030년
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 노르웨이
- 덴마크
- 스웨덴
아시아태평양
- 국가별, 2018-2030년
- 일본
- 중국
- 인도
- 한국
- 호주
- 태국
라틴아메리카
- 국가별, 2018-2030년
- 브라질
- 아르헨티나
중동 및 아프리카
- 국가별, 2018-2030년
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일, 상장 기업
- Amgen Inc.
- Eli Lilly and Company
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- GSK plc
- Radius Health, Inc.
- UCB SA
- Teva Pharmaceutical Industries Ltd.
- F. Hoffmann-La Roche Ltd

SHW

영문 목차

영문목차

Osteoporosis Drugs Market Growth & Trends:

The global osteoporosis drugs market size is expected to reach USD 18.8 billion by 2030 and is projected to grow at a CAGR of 3.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Osteoporosis Drugs Market Report Highlights:

Branded drugs held the dominant share of the product segment in 2024. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy
Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies
In 2024, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics
Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care
The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Type
- 1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Osteoporosis Drugs Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis

Chapter 4. Osteoporosis Drugs Market: Drug Class Business Analysis

4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Branded
- 4.4.1. Branded Market, 2018 - 2030 (USD Million)
4.5. Generics
- 4.5.1. Generics Market, 2018 - 2030 (USD Million)

Chapter 5. Osteoporosis Drugs Market: Type Business Analysis

5.1. Type Market Share, 2024 & 2030
5.2. Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
5.4. Bisphosphonates
- 5.4.1. Bisphosphonates Market, 2018 - 2030 (USD Million)
5.5. Parathyroid Hormone Therapy
- 5.5.1. Parathyroid Hormone Therapy Market, 2018 - 2030 (USD Million)
5.6. Calcitonin
- 5.6.1. Calcitonin Market, 2018 - 2030 (USD Million)
5.7. Selective Estrogen Inhibitors Modulator (SERM)
- 5.7.1. Selective Estrogen Inhibitors Modulator (SERM) Market, 2018 - 2030 (USD Million)
5.8. Rank Ligand Inhibitors
- 5.8.1. Rank Ligand Inhibitors Market, 2018 - 2030 (USD Million)
5.9. Other Products
- 5.9.1. Other Products Market, 2018 - 2030 (USD Million)

Chapter 6. Osteoporosis Drugs Market: Distribution Channel Business Analysis

6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
6.6. Online Pharmacies
- 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Osteoporosis Drugs Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
7.4. North America
- 7.4.1. North America Osteoporosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Regulatory Framework
  - 7.4.2.3. Competitive Insights
  - 7.4.2.4. U.S. Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Regulatory Framework
  - 7.4.3.3. Competitive Insights
  - 7.4.3.4. Canada Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Regulatory Framework
  - 7.4.4.3. Competitive Insights
  - 7.4.4.4. Mexico Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.5. Europe
- 7.5.1. Europe Osteoporosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Regulatory Framework
  - 7.5.2.3. Competitive Insights
  - 7.5.2.4. UK Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Regulatory Framework
  - 7.5.3.3. Competitive Insights
  - 7.5.3.4. Germany Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Regulatory Framework
  - 7.5.4.3. Competitive Insights
  - 7.5.4.4. France Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Regulatory Framework
  - 7.5.5.3. Competitive Insights
  - 7.5.5.4. Italy Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Regulatory Framework
  - 7.5.6.3. Competitive Insights
  - 7.5.6.4. Spain Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.7. Norway
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Regulatory Framework
  - 7.5.7.3. Competitive Insights
  - 7.5.7.4. Norway Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.8. Denmark
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Regulatory Framework
  - 7.5.8.3. Competitive Insights
  - 7.5.8.4. Denmark Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.5.9. Sweden
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Regulatory Framework
  - 7.5.9.3. Competitive Insights
  - 7.5.9.4. Sweden Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Osteoporosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Regulatory Framework
  - 7.6.2.3. Competitive Insights
  - 7.6.2.4. Japan Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Regulatory Framework
  - 7.6.3.3. Competitive Insights
  - 7.6.3.4. China Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Regulatory Framework
  - 7.6.4.3. Competitive Insights
  - 7.6.4.4. India Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. South Korea
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Regulatory Framework
  - 7.6.5.3. Competitive Insights
  - 7.6.5.4. South Korea Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.6. Australia
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Regulatory Framework
  - 7.6.6.3. Competitive Insights
  - 7.6.6.4. Australia Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Regulatory Framework
  - 7.6.7.3. Competitive Insights
  - 7.6.7.4. Thailand Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Osteoporosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Regulatory Framework
  - 7.7.2.3. Competitive Insights
  - 7.7.2.4. Brazil Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Regulatory Framework
  - 7.7.3.3. Competitive Insights
  - 7.7.3.4. Argentina Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
7.8. MEA
- 7.8.1. MEA Osteoporosis Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Regulatory Framework
  - 7.8.2.3. Competitive Insights
  - 7.8.2.4. South Africa Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Regulatory Framework
  - 7.8.3.3. Competitive Insights
  - 7.8.3.4. Saudi Arabia Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Regulatory Framework
  - 7.8.4.3. Competitive Insights
  - 7.8.4.4. UAE Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Regulatory Framework
  - 7.8.5.3. Competitive Insights
  - 7.8.5.4. Kuwait Osteoporosis Drugs Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Amgen Inc.
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Eli Lilly and Company
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Merck & Co., Inc.
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Novartis AG
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Pfizer Inc.
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. GSK plc
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Radius Health, Inc.
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. UCB S.A.
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. Teva Pharmaceutical Industries Ltd.
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. F. Hoffmann-La Roche Ltd
  - 8.5.10.1. Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Product Benchmarking
  - 8.5.10.4. Strategic Initiatives

한글목차

골다공증 치료 시장의 성장과 동향

골다공증 치료 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 골다공증 치료 시장의 변수, 동향, 범위

제4장 골다공증 치료 시장 : 약제 클래스 비즈니스 분석

제5장 골다공증 치료 시장 : 유형별 비즈니스 분석

제6장 골다공증 치료 시장 : 유통 채널 사업 분석

제7장 골다공증 치료 시장 : 지역별, 추정 및 예측분석